

ELITRA.009A



PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Forsyth et al.  
Appl. No. : 09/741,669  
Filed : December 19, 2000  
For : GENES IDENTIFIED AS  
REQUIRED FOR  
PROLIFERATION OF E. COLI  
Examiner : Frank Lu  
Group Art Unit : 1634

DECLARATION UNDER 37 C.F.R. § 1.132**Mail Stop AF**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

I, R. Allyn Forsyth, declare as follows:

1. I am one of the inventors of the subject matter claimed in the above-referenced patent application.
2. I am familiar with the specification of the present patent application, including the methods described therein and the details of the working examples that are described therein.
3. I have extensive experience in the field of microbial genetics and molecular biology as evidenced by my attached curriculum vitae (Exhibit A)
4. This Declaration is being submitted to demonstrate antisense nucleic acids complementary to a portion of the *E. coli* *yidC* gene, including SEQ ID NO: 60, inhibit the proliferation of *E. coli*. This Declaration also demonstrates that antisense nucleic acids complementary to a portion of the *Staphylococcus aureus* *yidC* gene, which were identified substantially as described in the present specification, inhibit the proliferation of *Staphylococcus aureus*.
5. As described in the specification of the present application, and discussed in more detail below, by identifying antisense nucleic acids which inhibit proliferation a number of proliferation-required genes as well as their proliferation-required gene products were identified

in *E. coli*. Among the inhibitory antisense nucleic acids discovered from *E. coli* was the antisense nucleic acid with the Clone ID No. E1M10000118B05. This clone is listed as an inhibitory antisense nucleic acid in Table 1 of the present application and has been given the Sequence Identification Number of SEQ ID NO: 60. The nucleotide sequence of this inhibitory antisense nucleic acid is present in the Sequence Listing of the present application as SEQ ID NO: 60.

6. Antisense nucleic acids capable of inhibiting the activity or level of a gene product encoded by a proliferation-required gene, including the inhibitory antisense nucleic acid having the nucleotide sequence of SEQ ID NO: 60, were identified prior to filing the present patent application using the procedure described in Examples 1 and 2 of this patent application. This procedure is also described below.

a. A library of nucleic acid sequences derived from the *E. coli* chromosome was generated by shearing the *E. coli* chromosome. In particular, random fragments of *E. coli* genomic DNA were generated by DNase I digestion, made blunt-ended with T4 polymerase, and cloned into the multiple cloning site (MCS) of the inducible expression vectors, pLEX5BA and pLEX5BA-3'.

b. Both pLEX5BA and pLEX5BA-3' are expression vectors which contain a *lac* promoter/operator sequence upstream of the multiple cloning site (MCS) such that the transcription of any nucleic acid fragment that is inserted into the MCS can be induced by adding IPTG to the culture. pLEX5BA-3' is derived from pLEX5BA but differs in that it also includes a T7 transcriptional terminator downstream of the MCS. This terminator prevents transcriptional read through thus allowing only the nucleic acid fragment inserted into the multiple cloning site to be transcribed. Each of these vectors also contains antibiotic resistance genes, such as the ampicillin resistance gene, for use in plasmid selection and maintenance.

c. The restriction site that was used for cloning the sheared genomic fragments into the expression vectors was the *Sma*I site. *Sma*I is a restriction enzyme which cuts DNA leaving blunt ends. Since the genomic fragments were also blunt ended, these fragments were inserted into the expression vector in either a forward orientation (such that the sense strand of the fragment was transcribed) or a reverse orientation (such that the antisense strand of the fragment was transcribed).

d. The library of expression vectors containing the genomic fragments was then transformed into *E. coli* and cultures were grown overnight in the presence of carbenicillin. Plasmids from the overnight cultures were harvested, purified and then re-transformed into *E. coli*. Resulting transformants were plated on LB agar supplemented with carbenicillin thereby generating plates having approximately 500 colonies each. Single colonies were subjected to robotic picking, arrayed into wells of 384 well culture dishes containing liquid LB supplemented with carbenicillin and then incubated for 16 hours at room temperature.

- e. To study the effect of transcription of the genomic inserts on the proliferation of cells plated on solid medium,  $10^2$ ,  $10^3$ ,  $10^4$ ,  $10^5$ ,  $10^6$ ,  $10^7$  and  $10^8$  fold dilutions of each overnight culture were prepared. Aliquots of from 0.5 to 3  $\mu$ l of these dilutions were spotted on selective agar plates with or without 1 mM IPTG. After overnight incubation, the plates were compared to assess the sensitivity of the clones to IPTG. Clones that grew similarly at all dilutions on both media were scored as a negative and were no longer considered. Clones that grew on the non-IPTG-containing medium but failed to grow at the same serial dilution on medium containing 1 mM IPTG were given a score based on the differential. For example, if the clone grew at a serial dilution of  $10^4$  on the IPTG-containing plate and grew at a serial dilution of  $10^8$  on the non-IPTG-containing plate, then the corresponding clone received a score of "4" representing the log difference in growth observed.
- f. To study the effects of transcriptional induction in liquid medium, growth curves were carried out by back diluting overnight cultures 1:200 into fresh media with or without IPTG and measuring the OD<sub>450</sub> every 30 minutes (min).
- g. Of the numerous clones tested, some were identified as containing nucleic acid sequences that inhibited *E. coli* proliferation after IPTG induction. Plasmid DNA was recovered from each of these clones then sequenced to determine the number of unique inhibitory sequences that were expressed.
- h. The sequence of each unique inhibitory nucleic acid was then used to determine the full-length sequence of the *E. coli* gene corresponding to the insert sequence. In particular, identification of the *E. coli* gene sequence was performed by comparing the sequence of the unique inhibitory nucleic acid to known *E. coli* sequences in GenBank using BLAST version 1.4 or version 2.0.6 as described in Example 3 of the present application.
7. Using the method described above, at least 93 of the inhibitory nucleic acids were found to be unique antisense sequences complementary to at least a portion of the sense strand of an *E. coli* gene. One of the inhibitory antisense nucleic acids discovered during this screen was found to be complementary to a portion of the *E. coli* gene *yidC*. Expression of this antisense nucleic acid resulted in a reduction in cellular proliferation such that a dose of cells 100 times greater than the number of cells required to form a colony on a plate lacking IPTG was required to form a colony on a plate containing 1 mM IPTG. This effect is indicated by the score of "2" that is listed in the column entitled "score" for plate well number B5 (highlighted in yellow) in Exhibit B. Since the plate was numbered E1M10000118, the clone in well B5 was given the Clone ID Number E1M10000B05 (B05). This is the Clone ID Number that corresponds to SEQ ID NO: 60 in TABLE I of the present patent application. As described in the Sequence Listing of the present patent application, the antisense nucleic acid of SEQ ID NO: 60 has a nucleotide sequence of 92 bases that is completely contained within the coding region of the *E. coli yidC* gene.
8. In a second screening experiment, which was conducted using methods substantially identical to those described above, a second antisense nucleic acid, which was found to inhibit *E. coli* proliferation, was identified as being complementary to a least a portion of the *yidC* gene. This 326 bp antisense nucleic acid was given the Clone ID No. E1M10000288G07 (G07). As with SEQ ID

NO: 60, this new antisense clone inhibited *E. coli* proliferation by a score of "2," which means that a dose of cells 100 times greater than the number of cells required to form a colony on a plate lacking IPTG was required to form a colony on a plate containing 1 mM IPTG. (See Exhibit C, yellow highlighting). Amplification of the plasmid sequence using primers flanking the insert produced a band of the expected size (326 bp) demonstrating that the G07 antisense nucleic acid was present in the cell. (Exhibit C). When cells containing G07 antisense were inoculated onto IPTG plates in sufficient concentration to exhibit visible growth, only a very small colony was formed. This additional phenotypic feature is indicated by the letter "t" in the column entitled "phenotype" in Exhibit D.

9. The length of the G07 inhibitory antisense nucleic acid was found to be 326 nucleotides. Upon comparison of the G07 nucleotide sequence with the known sequence of the *E. coli* genome, it was found that G07 maps to the region between 81.5 and 84.5 minutes of the *E. coli* chromosome. Upon further analysis it was determined that G07 overlaps 157 nucleotides of the 3'-end of the *yidC* coding region.

10. A comparison of the locations of antisense clones B05 (SEQ ID NO: 60) and G07 with respect to the *E. coli yidC* gene showed that each of these antisense nucleic acids are complementary to separate regions of the *yidC* gene separated by approximately 800 base pairs. As such, clones B05 (SEQ ID NO: 60) and G07 are non-overlapping inhibitory antisense nucleic acids which are complementary to different regions of the *yidC* gene.

11. Antisense nucleic acids complementary to the *yidC* gene of organisms other than *E. coli* inhibit proliferation of those organisms. We recently completed a screen of approximately 315,000 *Staphylococcus aureus* clones to identify antisense nucleic acids capable of inhibiting the expression of proliferation-required genes. One of the many inhibitory antisense nucleic acids that was identified was an antisense nucleic acid complementary to at least a portion of the *yidC* gene from *Staphylococcus aureus* (the *yidC* gene is also known as SAV2090 in *S. aureus*).

12. The screen for inhibitory antisense nucleic acids from *S. aureus* was preformed using essentially the methods described in the present application for *E. coli*. The details of this procedure are described below.

a. *Staphylococcus aureus* genomic DNA was sheared as described in the above procedure except that in some instances the enzyme used to digest the DNA was *Sau3A*. Fragments up to 800 bp were size selected using gel electrophoresis and then cloned into the MCS of the expression vector pXylT5-P15a.

b. pXylT5-P15a contains a T5 promoter and a xylose operator sequence upstream of the multiple cloning site (MCS) arranged such that the transcription of any nucleic acid fragment that is inserted into the MCS can be induced by adding the sugar xylose to the culture. pXylT5-P15a also includes a T7 transcriptional terminator downstream of the MCS. This terminator prevents transcriptional read through thus allowing only the nucleic acid fragment inserted into the multiple cloning site to be transcribed.

- c. Genomic fragments were cloned into the MCS of pXylT5-P15a without respect to orientation as described in the above procedure. Thus, if the fragment was inserted into the cloning site in a forward orientation, the sense strand of the fragment would be transcribed. In contrast, if the fragment was inserted in a reverse orientation, the antisense strand of the fragment would be transcribed.
- d. The library of expression vectors containing the genomic fragments was transformed into electrocompetent *E. coli* strain XL1-Blue MRF' and plated on LB medium supplemented with carbenicillin. Resulting colonies numbering  $5 \times 10^5$  or greater were scraped and combined, and were then subjected to plasmid purification.
- e. The purified library was transformed into electrocompetent *Staphylococcus aureus* RN4220. Resulting transformants were plated on agar containing LB + 0.2% glucose (LBG medium) supplemented with chloramphenicol thereby generating plates having approximately 500 colonies each. Single colonies were subjected to robotic picking, arrayed into wells of 384 well culture dishes containing liquid LBG supplemented with chloramphenicol and then incubated for 16 hours at 37°C.
- f. To study the effect of transcriptional induction on solid medium, overnight cultures were serially diluted as described above. Aliquots of from 0.5 to 3  $\mu$ l of these dilutions were spotted on selective agar plates with or without 2% xylose. After overnight incubation, the plates were compared to assess the sensitivity of the clones to 2% xylose. Clones were scored for growth inhibition in the presence of 2% xylose as described above.
- g. Of the 315,000 clones tested, about 4000 were identified as containing nucleic acid sequences that inhibited *S. aureus* proliferation after xylose induction. Plasmid DNA was recovered from each of these clones then sequenced to determine the number of unique inhibitory sequences that were expressed.
- h. The sequence of each unique inhibitory nucleic acid was then used to determine the full-length sequence of the *S. aureus* gene corresponding to the insert sequence. In particular, identification of the *S. aureus* gene sequence was performed by comparing the sequence of the unique inhibitory nucleic acid to known *S. aureus* sequences in GenBank using BLAST.
13. Using the method described above, at least 2100 of the inhibitory nucleic acids were found to be unique antisense sequences complementary to at least a portion of the sense strand of a *S. aureus* gene. Several of the inhibitory antisense nucleic acids discovered during this screen were found to be complementary to a portion of the *S. aureus* gene SAV2090 (see Exhibit E). The polypeptide produced by the *S. aureus* SAV2090 gene was found to include the highly evolutionarily conserved YidC region (as shown in Exhibit F), and thus, SAV2090 was identified as the *S. aureus* counterpart of the *yidC* gene in *E. coli*.
14. Although a number of antisense clones complementary to the SAV2090 gene were obtained, only a single antisense nucleic acid, S1M10000048E09 (S1-843A), was selected for

further study (see Exhibit G). First, the inhibitory ability of the S1-843A antisense was further characterized by determining the effect of the expression of S1-843A on the growth of *S. aureus* in broth culture for a range of inducer (xylose) concentrations. In a second study, the  $IC_{50}$  for xylose-mediated antisense expression was calculated from a dose response curve that was generated by determining the percentage of proliferation inhibition of cells treated with increasing concentrations of xylose as compared with untreated control cells. The methods, which were used to generate these data and which are described below, are essentially the same as the procedures described in Examples 1 and 9 of the present patent application.

a. To study the effects of transcriptional induction in liquid medium, growth curves were carried out by back diluting logarithmic cultures of *S. aureus* to an  $OD_{600}$  of 0.0002 using fresh media with varying concentrations of xylose and measuring the  $OD_{600}$  every 10 minutes over the course of twelve hours. In particular, *S. aureus* containing the above-described S1-843A antisense expression construct was used to test the effect of the induction anti-*yidC* antisense expression on *S. aureus* proliferation at fifteen different xylose concentrations ranging from 0 to 100 mM. The results of this experiment are displayed in Exhibit H.

b. To determine the  $IC_{50}$  for xylose-mediated S1-843A antisense expression, dose response curves were generated by monitoring the decrease in proliferation of *S. aureus* in response to increasing xylose concentration. In particular, the pXylT5-P15a vector containing S1-843A in an antisense orientation was introduced into *S. aureus* and isolates having the S1-843A expression construct were grown overnight in broth culture. The overnight culture was diluted 1:200 into fresh medium with or without xylose then distributed among the wells of a 96 well microtiter plate in 200  $\mu$ l aliquots. In particular, xylose was present in the medium at 100 mM, 75 mM, 50 mM, 37.5 mM, 25 mM, 18.75 mM, 12.5 mM, 9.38 mM, 6.25 mM, 4.69 mM, 3.13 mM, 2.34 mM, 1.56 mM, 1.17 mM and 0 mM. Cultures were grown in quadruplicate for each xylose concentration. Additionally, control cells were grown in quadruplicate without xylose. When the control cells (cultures without xylose) reached an  $OD_{600}$  of 0.1, the percent growth (relative to the control culture) for each of the xylose containing cultures was plotted against the log concentrations of xylose to produce a growth inhibitory dose response curve for xylose-mediated S1-843A antisense expression. The concentration of xylose that inhibits cell growth to 50% ( $IC_{50}$ ) as compared to the 0 mM xylose control (0% growth inhibition) was then calculated from the curve. The results of this experiment are displayed in Exhibit I.

15. The growth curves displayed in Exhibit H plot the optical density of cultures of *S. aureus*, which harbor the S1-843A antisense nucleic acid under the control of a xylose inducible expression vector, over a twelve hour time course. Each curve represents the proliferation of a culture grown in the presence of xylose ranging in concentration from 0 to 100 mM. These growth curves show that *S. aureus* grown in the presence of high xylose concentrations proliferated much less rapidly over the twelve hour time course than those cells exposed to little or no xylose. In general, as the concentration of xylose was increased, *S. aureus* proliferation decreased.

Appl. No. : 09/741,669  
Filed : December 19, 2000

16. The dose response curve displayed in Exhibit I illustrates that expression of the S1-843A antisense nucleic acid induced with approximately 7.13 mM xylose is sufficient to inhibit *S. aureus* proliferation by about 50%. At a concentration of approximately 16.0 mM xylose, *S. aureus* proliferation is inhibited by about 90%.

17. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issuing therefrom.

Dated:

August 8, 2003

By:

R. Allyn Forsyth  
R. Allyn Forsyth

SADOC SVLHJLH-2129.DOC  
072503

*Curriculum vitae*  
**Roger "Allyn" Forsyth**

Residence  
1135 Beryl Street  
San Diego, CA 92109  
(858) 272-6937  
Email: aforsyt1@san.rr.com

Work  
3510 Dunhill St  
San Diego, CA 92121  
(858) 410-3017, Fax (858) 410-3089  
Email: aforsyth@elitra.com

**Education:**

1989                      **B.S. in Biology**  
University of California at Los Angeles

1998                      **Ph. D. in molecular biology** conferred jointly by  
San Diego State University and the  
University of California at San Diego.

Delayed degree two  
years to allow patent  
prosecution

**Management and corporate leadership accomplishments**

- Participated in securing first round funding for start-up company.
- Assisted in licensing discovery method from university
- Responsible for meeting major stage two funding milestones (patent filings, personnel recruitment, equipment acquisition, and scientific proof of concept).
- Responsible for strategic development plans, budgets, FTE and equipment allocation.
- Appointed to corporate Joint Research Committees
- Responsible for successful technology transfer for corporate partners.
- Managed as many as 7 direct reports while coordinating the efforts of over a dozen researchers, scientists and engineers.
- Recruited, trained, performed yearly evaluations and maintained high retention rates for direct reports over a 4 year period in an HTS environment.

**Summary of Scientific and Research skills**

- Experienced in assay development, primary HTS, compound profiling.
- Established microbiologist with demonstrated creative molecular biology approaches in a variety of fungal, gram-positive and gram-negative microorganisms.
- Strong skills in technology adaptation in the field of genomics.
- Creative ability to "industrialize" micro and molecular techniques by adapting protocols to 384 well formats and/or high density arrays.
- Comfortable with custom robotic system design, optics and data integration.
- Experienced with bioinformatic tools, analysis and computing platforms (Unix, Vax, PC, Mac), design of Access databases, Excel macros and other data tools.



**Experience:**

2001-Present

**Scientific Group Leader at Elitra Pharmaceuticals**

Team leader of an interdisciplinary group developing Elitra's Target Array technology from proof of concept to production level compound screening. The Target Array presently provides the relative sensitization and significance with which over 200 essential *S. aureus* genes respond to tested compounds simultaneously. I designed and oversaw development of custom robotics platform, the biological strategy for building, implementing and ultimately the transfer of the technology to corporate partners

I have continued development of target-based assays for a collaborator. 10 assays against various essential genes were delivered in a 1-year period.

2000-2001

**Senior Scientist at Elitra Pharmaceuticals.**

Led a team developing cell based target assays in bacteria. Industrialized the process of assay development allowing for parallel processing of multiple targets while collecting "high content" data over time (cell growth at altered levels of target protein, response of cell to dozens of metabolic inhibitors, target mRNA levels etc.). Strategy allowed for prioritization of hundreds of targets and delivery of over a dozen assays (in all major cellular pathways) for collaborators in an 8-month period. Responsible for technology transfer of assay methodologies to collaborators and in managing transitions to HTS.

Directed the establishment of a BioRepository containing over 10,000 engineered strains and plasmids. Data on all fungal, bacterial and plasmid entities is maintained on a customized relational database.

Established and executed novel HTS in 384 formats allowing parallel testing of many targets against more than 20,000 samples per day. Directed secondary screening and profiling of compounds against panels of bacteria.

1998 - 2000

**Research Scientist II / Scientific Cofounder at Elitra Pharmaceuticals (formerly Rajyabiotics)**

Managed a team of 4 - 7 Research Associates engaged in an essential gene discovery program. Program successfully screened more than 6 pathogens during this time and has filed patents on over 3000 genes to date. Responsible for the industrialization of Elitra's core gene discovery process by evaluating, acquiring and integrating robotic equipment. Initiated and managed collaborations to develop new equipment and software to increase efficiency.

Managed and industrialized the company media lab. Increased media production to an excess of 1500 units per day (petri plates, 96 and 384 microtiter plates) and maintained general support of a lab of 30 research personnel while decreasing to 1 FTE. Achieved goals through

custom automation and integrated tracking and ordering systems.

- Developed core protocols for processing gram-negative and gram-positive bacterial organisms using patented gene discovery technique.
- Team processed up to 1,500,000 clones /month as compared to previous efforts of 20,000 /month resulting in discovery rates as high as 300 genes per month.
- Set up databases and tracking systems.

1997 - 1998

**Research Scientist / Scientific Co-founder at RajyaBiotics Pharmaceuticals**

As a scientific co-founder of the company I had multiple roles. I assisted in achieving milestones for seed funding (Series A and B), interviewed and recruited scientific personnel (5 Ph.D.s, 8 RAs), prepared patent and other intellectual data for the essential gene discovery technique, and aided in the design and equipment choices of 6,000 sq ft of laboratory space. The company was based on an essential gene discovery technology that I co-invented and helped license from SDSU.

- Developed key protocols and molecular tools including core vectors and primers, genomic library protocols, screening and validation methodologies.
- Devised approaches to study individual essential genes using inverse PCR strategies or random fractionation of the target genes of interest.

Identified key mechanisms of antisense RNA inhibition in gram-negative organisms.

1992 - 1997

**Consultant**

Macromolecular Structural Analysis Resources Center.

Responsibilities included organizing and presenting workshops to California State University subscribers in San Francisco, Pomona and Fullerton, on the use of GCG and STADEN programs on VAX and UNIX platforms. Consulting with users to ensure successful application of programs.

1991 - 1997

**Teaching Associate**

Department of Biology, SDSU.

Duties included preparing lectures, assignments and grading.

1996

**Instructor / Research Specialist**

Defense Conversion class.

Developed and taught curriculum on computer analysis in molecular

biology and uses of the internet in science to students converted from defense industry to molecular biology.

- 1996 National Institute of Health Workshop for CSU faculty and staff.  
Developed curriculum and taught techniques for polymerase chain reaction (PCR), cloning, and computer analysis of problems in molecular biology.
- 1989 - 1991 **Research Technician**  
Department of Molecular Biology, SDSU.  
Responsibilities included carrying out research projects in bacterial cell cycle, cloning, and protein purification, ordering of supplies, lab maintenance and organization, radiation safety officer.
- 1988 - 1989 **Lab Assistant**  
Biological chemistry department, UCLA.  
Carried out and assisted in experiments studying clathrin mediated transport in yeast.

**Awards:**

- 1991 - 1996 National Institute of Health Predoctoral Fellow.
- 1995 - 1997 ARCS Scholar.

**Presentations and Abstracts:**

- April 18 - Ines Gil, Amy L. Svitil, **Allyn Forsyth**, Vicky G. Newman, Aaron V. Pontsler, and Judith W. Zyskind. DnaA protein effects of ppGpp on *dnaA* gene expression, effects of methylation on DnaA binding to DNA. Poster presentation at the 22nd Annual Keystone symposium on Bacterial Chromosomes.
- 25, 1993
- February **Allyn Forsyth**, and Judith W. Zyskind. Is Newly Synthesized DnaA Required for Initiation of Replication? Poster presentation at the Lake Arrowhead Genetics Symposium.
- 28 -30, 1994
- June, **Allyn Forsyth**, Jamie Froelich, and Judith W. Zyskind. Intrinsic bends in the *dnaA* promoter region. Poster presentation at the EMBO Cell Cycle Symposium. Stockholm, Norway.
- 1995

**Publications and Patents:**

- 1998 Dalia Y. Kalabat, Jamie M. Froelich, Trung P. Phuong, **R. Allyn Forsyth**, Judith W. Zyskind. 1998. Chitobiase, a new reporter enzyme. *BioTechniques* 25:1030-35

- 2001      **U.S. Patent No. 6,228,579**  
Title: Method for Identifying Microbial Proliferation Genes  
Filing Date:            November 14, 1997  
Assignee:              San Diego State University    (Exclusively licensed to Elitra)  
Issue Date:             May 8, 2001
- 2002      **R. Allyn Forsyth, Robert J. Haselbeck, Kari L. Ohlsen, Robert T. Yamamoto, Howard Xu, John D. Trawick, Daniel Wall, Liangsu Wang, Vickie Brown-Driver, Jamie M. Froelich, Kedar G. C., Paula King, Melissa McCarthy, Cheryl Malone, Brian Misiner, David Robbins, Zehui Tan, Zhan-yang Zhu, Grant Carr, Deborah A. Mosca, Carlos Zamudio, J. Gordon Foulkes, and Judith W. Zyskind. A Genome Wide Strategy for the Identification of Essential Genes in the Pathogen, *Staphylococcus aureus*. 2002. Molecular Microbiology 43(6) 1387-1400**
- 2003      **U.S. Patent No. 6,589,738**  
Title: Genes Essential for Microbial Proliferation and Antisense Thereto  
Filing Date:            November 9, 2000  
Priority Date:           November 9, 1999  
Assignee:              Elitra Pharmaceuticals, Inc.  
Issue Date:             July 8, 2003
- 2003      **U.S. Patent Application Serial No. 09/492,709**  
Title: Genes Identified as Essential for Proliferation in *Escherichia coli*  
Filing Date:            January 27, 2000  
Priority Date: January 27, 1999  
Assignee:              Elitra Pharmaceuticals, Inc.  
Status:                 Allowed

DATE 6/16/99

Batch #

109

Initial Sensitives

Plate ID

EIM10000118

Scored by P. Bauer

well #	row	column	score	well #	row	column	score	well #	row	column	score
A1	1	1	1	A3	2	1	0	A5	3	1	0
<del>A2</del>	1	2	<del>1</del>	A4	2	2	0	A6	3	2	0
<del>B1</del>	1	3	<del>2</del>	B3	2	3	1	<del>B5</del>	3	3	2
B2	1	4	0	<del>B4</del>	2	4	5	<del>B6</del>	3	4	2
<del>C1</del>	1	5	<del>1</del>	C3	2	5	1	<del>C5</del>	3	5	2
<del>C2</del>	1	6	<del>1</del>	<del>C4</del>	2	6	2	C6	3	6	1
<del>D1</del>	1	7	<del>1</del>	D3	2	7	0	D5	3	7	1
<del>D2</del>	1	8	<del>1</del>	<del>D4</del>	2	8	5	<del>D6</del>	3	8	2
<del>E1</del>	1	9	<del>1</del>	E3	2	9	1	<del>E5</del>	3	9	5
<del>E2</del>	1	10	<del>1</del>	<del>E4</del>	2	10	<del>4</del>	E6	3	10	1
F1	1	11	0	F3	2	11	1	F5	3	11	1
<del>F2</del>	1	12	<del>1</del>	F4	2	12	1	<del>F6</del>	3	12	OT
G1	1	13	0	G3	2	13	1	G5	3	13	1
<del>G2</del>	1	14	<del>1</del>	<del>G4</del>	2	14	<del>2</del>				
H1	1	15	0	H3	2	15	0				
H2	1	16	0	<del>H4</del>	2	16	<del>6</del>				

← y:dc

well #	row	column	score	well #	row	column	score	v
A7	1	1	0	A9	2	1	0	
A8	1	2	0	A10	2	2	0	
<del>B7</del>	1	3	<del>1</del>	B9	2	3	1	
B8	1	4	1	B10	2	4	0	
<del>C7</del>	1	5	<del>3</del>	C9	2	5	0	
<del>C8</del>	1	6	<del>3</del>	C10	2	6	0	
D7	1	7	1	D9	2	7	0	
D8	1	8	1	D10	2	8	0	
E7	1	9	0	E9	2	9	1	
<del>E8</del>	1	10	<del>6</del>	<del>E10</del>	2	10	<del>2</del>	
<del>F7</del>	1	11	<del>2</del>	<del>F9</del>	2	11	<del>3</del>	
F8	1	12	1	F10	2	12	1	
G7	1	13	1	G9	2	13	1	
G8	1	14	0	G10	2	14	0	
<del>H7</del>	1	15	<del>7</del>	H9	2	15	0	
<del>H8</del>	1	16	<del>3</del>	<del>H10</del>	2	16	<del>7</del>	

109 - EIM10000118 H1 06/16/99  
IMAGE SIZE (640 x 480 x 8).  
INT PERIOD = 0.83 SEC.  
ACQUIRED WED JUN 16 08:55:33 1999.

STRATAGENE EAGLE EYE II

06/16/99

08:55:48

EXHIBIT B


BEST AVAILABLE COPY

EXHIBIT C

DATE 8/6/01 Batch # 180 Initial Sensitives Plate ID E1m1...0288 Scored by Ann

well #	row	column	score	well #	row	column	score	well #	row	column	score
A1	1	1	Vector	A3	2	1	3t	A5	3	1	1t
A2	1	2	3t	A4	2	2	2t	A6	3	2	6
B1	1	3	8	B3	2	3	7	B5	3	3	3t
B2	1	4	8	B4	2	4	0t	B6	3	4	4t
C1	1	5	8	C3	2	5	0	C5	3	5	1
C2	1	6	7	C4	2	6	8	C6	3	6	8
D1	1	7	7	D3	2	7	8	D5	3	7	7
D2	1	8	8	D4	2	8	8	D6	3	8	7
E1	1	9	0t	E3	2	9	7	E5	3	9	2t
E2	1	10	8	E4	2	10	0t	E6	3	10	Vector
F1	1	11	0	F3	2	11	0t	F5	3	11	0
F2	1	12	0t	F4	2	12	0t	F6	3	12	0t
G1	1	13	3t	G3	2	13	8	G5	3	13	8
G2	1	14	0t	G4	2	14	8	G6	3	14	8
H1	1	15	Sterile	H3	2	15	3t	H5	3	15	3t
H2	1	16	8	H4	2	16	0t	H6	3	16	0t

well #	row	column	score	well #	row	column	score	well #	row	column	score
A7	1	1	7	A9	2	1	8	A11	3	1	8
A8	1	2	8	A10	2	2	8	A12	3	2	8
B7	1	3	8	B9	2	3	6	B11	3	3	6
B8	1	4	5t	B10	2	4	6	B12	3	4	6
C7	1	5	7	C9	2	5	7	C11	3	5	7
C8	1	6	6	C10	2	6	8	C12	3	6	8
D7	1	7	Vector	D9	2	7	3t	D11	3	7	3t
D8	1	8	0t	D10	2	8	8	D12	3	8	8
E7	1	9	8	E9	2	9	4t	E11	3	9	4t
E8	1	10	8	E10	2	10	4t	E12	3	10	4t
F7	1	11	8	F9	2	11	8	F11	3	11	8
F8	1	12	0t	F10	2	12	8	F12	3	12	8
G7	1	13	2t	G9	2	13	0	G11	3	13	0
G8	1	14	0	G10	2	14	8	G12	3	14	8
H7	1	15	8	H9	2	15	8	H11	3	15	8
H8	1	16	8	H10	2	16	8	H12	3	16	8



BEST AVAILABLE COPY


Storage Code	Clone ID	Locus	Locus Description	Strain	Plasmid	Library	phen	Score	% of clones	% of total
SE800	EIM10000214A0							8		
SE802	EIM10000214B0							4		
SE803	EIM10000214C0							51		
SE804	EIM10000214D0							6		
SE805	EIM10000214E0							3		
SE806	EIM10000214F0							0T		
SE807	EIM10000214G0							4		
SE808	EIM10000214H0							8		
SE809	EIM10000214I0							8		
SE810	EIM10000214J0							7		
SE811	EIM10000214K0							51		
SE812	EIM10000214L0							7		
SE813	EIM10000214M0							2T		
SE814	EIM10000214N0							8		
SE815	EIM10000214O0							2T		
SE816	EIM10000214P0							7		
SE817	EIM10000214Q0							6		
SE818	EIM10000214R0							7		
SE819	EIM10000214S0							7		
SE820	EIM10000214T0							7		
SE821	EIM10000214U0							7		
SE822	EIM10000214V0							7		
SE823	EIM10000214W0							7		
SE824	EIM10000214X0							7		
SE825	EIM10000214Y0							7		
SE826	EIM10000214Z0							7		
SE827	EIM10000215A0							7		
SE828	EIM10000215B0							7		
SE829	EIM10000215C0							7		
SE830	EIM10000215D0							7		
SE831	EIM10000215E0							7		
SE832	EIM10000215F0							7		
SE833	EIM10000215G0							7		
SE834	EIM10000215H0							7		
SE835	EIM10000215I0							7		
SE836	EIM10000215J0							7		
SE837	EIM10000215K0							7		
SE838	EIM10000215L0							7		
SE839	EIM10000215M0							7		
SE840	EIM10000215N0							7		
SE841	EIM10000215O0							7		
SE842	EIM10000215P0							7		
SE843	EIM10000215Q0							7		
SE844	EIM10000215R0							7		
SE845	EIM10000215S0							7		
SE846	EIM10000215T0							7		
SE847	EIM10000215U0							7		
SE848	EIM10000215V0							7		
SE849	EIM10000215W0							7		
SE850	EIM10000215X0							7		
SE851	EIM10000215Y0							7		
SE852	EIM10000215Z0							7		
SE853	EIM10000216A0							7		
SE854	EIM10000216B0							7		
SE855	EIM10000216C0							7		
SE856	EIM10000216D0							7		
SE857	EIM10000216E0							7		
SE858	EIM10000216F0							7		
SE859	EIM10000216G0							7		
SE860	EIM10000216H0							7		
SE861	EIM10000216I0							7		
SE862	EIM10000216J0							7		
SE863	EIM10000216K0							7		
SE864	EIM10000216L0							7		
SE865	EIM10000216M0							7		
SE866	EIM10000216N0							7		
SE867	EIM10000216O0							7		
SE868	EIM10000216P0							7		
SE869	EIM10000216Q0							7		
SE870	EIM10000216R0							7		
SE871	EIM10000216S0							7		
SE872	EIM10000216T0							7		
SE873	EIM10000216U0							7		
SE874	EIM10000216V0							7		
SE875	EIM10000216W0							7		
SE876	EIM10000216X0							7		
SE877	EIM10000216Y0							7		
SE878	EIM10000216Z0							7		
SE879	EIM10000217A0							7		
SE880	EIM10000217B0							7		
SE881	EIM10000217C0							7		
SE882	EIM10000217D0							7		
SE883	EIM10000217E0							7		
SE884	EIM10000217F0							7		
SE885	EIM10000217G0							7		
SE886	EIM10000217H0							7		
SE887	EIM10000217I0							7		
SE888	EIM10000217J0							7		
SE889	EIM10000217K0							7		
SE890	EIM10000217L0							7		
SE891	EIM10000217M0							7		
SE892	EIM10000217N0							7		
SE893	EIM10000217O0							7		
SE894	EIM10000217P0							7		
SE895	EIM10000217Q0							7		
SE896	EIM10000217R0							7		
SE897	EIM10000217S0							7		
SE898	EIM10000217T0							7		
SE899	EIM10000217U0							7		
SE900	EIM10000217V0							7		
SE901	EIM10000217W0							7		
SE902	EIM10000217X0							7		
SE903	EIM10000217Y0							7		
SE904	EIM10000217Z0							7		
SE905	EIM10000218A0							7		
SE906	EIM10000218B0							7		
SE907	EIM10000218C0							7		
SE908	EIM10000218D0							7		
SE909	EIM10000218E0							7		
SE910	EIM10000218F0							7		
SE911	EIM10000218G0							7		
SE912	EIM10000218H0							7		
SE913	EIM10000218I0							7		
SE914	EIM10000218J0							7		
SE915	EIM10000218K0							7		
SE916	EIM10000218L0							7		
SE917	EIM10000218M0							7		
SE918	EIM10000218N0							7		
SE919	EIM10000218O0							7		
SE920	EIM10000218P0							7		
SE921	EIM10000218Q0							7		
SE922	EIM10000218R0							7		
SE923	EIM10000218S0							7		
SE924	EIM10000218T0							7		
SE925	EIM10000218U0							7		
SE926	EIM10000218V0							7		
SE927	EIM10000218W0							7		
SE928	EIM10000218X0							7		
SE929	EIM10000218Y0							7		
SE930	EIM10000218Z0							7		
SE931	EIM10000219A0							7		
SE932	EIM10000219B0							7		
SE933	EIM10000219C0							7		
SE934	EIM10000219D0							7		
SE935	EIM10000219E0							7		
SE936	EIM10000219F0							7		
SE937	EIM10000219G0							7		
SE938	EIM10000219H0							7		
SE939	EIM10000219I0							7		
SE940	EIM10000219J0							7		
SE941	EIM10000219K0							7		
SE942	EIM10000219L0							7		
SE943	EIM10000219M0							7		
SE944	EIM10000219N0							7		
SE945	EIM10000219O0							7		
SE946	EIM10000219P0							7		
SE947	EIM10000219Q0							7		
SE948	EIM10000219R0							7		
SE949	EIM10000219S0							7		
SE950	EIM10000219T0							7		
SE951	EIM10000219U0							7		
SE952	EIM10000219V0							7		
SE953	EIM10000219W0							7		
SE954	EIM10000219X0							7		
SE955	EIM10000219Y0							7		
SE956	EIM10000219Z0							7		
SE957	EIM10000220A0							7		
SE958	EIM10000220B0							7		
SE959	EIM10000220C0							7		
SE960	EIM10000220D0							7		
SE961	EIM10000220E0							7		
SE962	EIM10000220F0							7		
SE963	EIM10000220G0							7		
SE964	EIM10000220H0							7		
SE965	EIM10000220I0							7		
SE966	EIM10000220J0							7		
SE967	EIM10000220K0							7		
SE968	EIM10000220L0							7		
SE969	EIM10000220M0							7		
SE970	EIM10000220N0							7		
SE971	EIM10000220O0							7		
SE972	EIM10000220P0							7		
SE973	EIM10000220Q0							7		
SE974	EIM10000220R0							7		
SE975	EIM10000220S0							7		
SE976	EIM10000220T0							7		
SE977	EIM10000220U0							7		
SE978	EIM10000220V0							7		

# Location of yidC Antisense within the Predicted yidC Operon Structure

# Operation ID: 3374

SAY2094, thid, chin, thie, SAY2090

2006P







Nucleotide

Protein

formatting

**BLAST**

Translations

Retrieve results for an  
RID

Your request has been successfully submitted and put into the Blast Queue.

Query = (290 letters)

Putative conserved domains have been detected, click on the image below for detailed results.



The request ID is 1059763433-0993-8122

**Format!** or **Reset!**

The results are estimated to be ready in 4 seconds but may be done sooner.

Please press "FORMAT!" when you wish to check your results. You may change the formatting options for your result via the form below and press "FORMAT!" again. You may also request results of a different search by entering any other valid request ID to see other recent jobs.

### Format

Show

[Graphical Overview](#)[Linkout](#)[Sequence Retrieval](#)NCBI-gi ☒ Alignment ☒ in Number of: Descriptions  ☒ Alignments  ☒Alignment view  ☒Format for PSI-  
BLASTwith inclusion threshold: Limit results by  or select from:  ☒Expect value  
range:  **BEST AVAILABLE COPY**


EXHIBIT F

# Genomic insert of yidC Antisense Clone

SIM10000048E09 (S1-843A) Sequence Length: 199

TCCCAACCAATCCAATACATTTTTCATTGGATCTACGAATGTATTG  
TAGAAAAAACCCACTACGTTTTTCAGGTTTAGAATAGTCACCAACCA  
GCCAAAAAAGACCATAATACCTAAAAAATAATGGTAGTAACGCTTTT  
TTCTTCATTTTTCACCTCTATCATTTATATTCACATAGGATTATTC  
TATCACATTAAATGAGT

# Growth Curve in Response to Xylose Dosing of S1-843A, *S. aureus* RN4220 carrying yidC antisense



# Xylose Dose Response of S1-843A at an $OD_{600} = 0.1$

S1-843A

